Abstract PD8-08: A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Cancer Therapies ◽

Anti Cancer ◽

Er Positive ◽

Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer

10.1158/1538-7445.sabcs19-p5-11-01 ◽

2020 ◽

Author(s):

Erika Hamilton ◽

Patricia LoRusso ◽

Cynthia Ma ◽

Neelima Vidula ◽

Rebecca G Bagley ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽

Receptor Modulator ◽

Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs20-pd1-09 ◽

2021 ◽

Author(s):

Ian Krop ◽

Kan Yonemori ◽

Shunji Takahashi ◽

Kenichi Inoue ◽

Takahiro Nakayama ◽

...

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Antibody Drug Conjugate ◽

Safety And Efficacy ◽

Epidermal Growth ◽

Antibody Drug

Abstract P1-18-36: The safety, tolerability, and pharmacokinetics of BAT8001 in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer: An open-label, dose-up, phase 1 study

10.1158/1538-7445.sabcs19-p1-18-36 ◽

2020 ◽

Author(s):

Shusen Wang ◽

Ruoxi Hong ◽

Liye Wang ◽

Fei Xu ◽

Wen Xia

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Phase 1 Study ◽

Label Dose ◽

Abstract P3-01-04: DETECT V – Expression analysis of human epidermal growth factor receptor 2 and estrogen receptor on circulating tumor cells of metastatic breast cancer patients

10.1158/1538-7445.sabcs18-p3-01-04 ◽

2019 ◽

Author(s):

T Fehm ◽

F Meier-Stiegen ◽

S Riethdorf ◽

B Rack ◽

F-A Taran ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

10.1158/1538-7445.sabcs18-ot1-03-01 ◽

2019 ◽

Author(s):

G Curigliano ◽

S Cresta ◽

Y-S Yap ◽

D Juric ◽

FP Duhoux ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

10.1158/1538-7445.sabcs19-pd7-07 ◽

2020 ◽

Author(s):

Virginia Kaklamani ◽

Aditya Bardia ◽

Sharon Wilks ◽

Amy Weise ◽

Donald Richards ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Final Analysis ◽

Phase 1 Study ◽

Abstract P1-01-15: DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients

10.1158/1538-7445.sabcs16-p1-01-15 ◽

2017 ◽

Author(s):

T Fehm ◽

F Meier-Stiegen ◽

S Riethdorf ◽

A Schramm ◽

A Polasik ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs17-p1-10-07 ◽

2018 ◽

Author(s):

M Campone ◽

J Sachdev ◽

GV Bianchi ◽

JT Beck ◽

N Martínez-Jáñez ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Randomized Phase Ii ◽

Abstract P5-11-02: Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer

10.1158/1538-7445.sabcs19-p5-11-02 ◽

2020 ◽

Author(s):

Mario Campone ◽

Aditya Bardia ◽

Gary A Ulaner ◽

Sarat Chandarlapaty ◽

Alice Gosselin ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

BMC Cancer ◽

10.1186/s12885-019-5890-z ◽

2019 ◽

Vol 19 (1) ◽

Author(s):

Mark Laible ◽

Kerstin Hartmann ◽

Claudia Gürtler ◽

Tobias Anzeneder ◽

Ralph Wirtz ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Molecular Subtypes ◽

Growth Factor Receptor ◽

Distant Recurrence ◽

Er Positive ◽